Earnings Call · Q3 FY2023·2023-11-07

Q3 23EPS +12.77%·Rev n/aQ2 23EPS -61.70%·Rev n/aQ1 23EPS +33.33%·Rev n/aQ4 22EPS -3.93%·Rev n/a⚠ consensus missing

Zymeworks Inc. ZYME

Shrinal Inamdar — Director of Investor Relations

Chris Astle — Chief Financial Officer

Paul Moore — Chief Medical Officer

−3.7%1d on move date−3.7% vs SPY3d−1.1%5d+3.5%

Research tier

Behavioral profile computed for 3 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more ZYME calls or request research access.

More ZYME calls Browse calls Request research access